Lucio Crinò, MD, Director, Department of Oncology, University Hospital of Perugia, Italy, discusses the results of the PROFILE 1007 trial that compared crizotinib with standard chemotherapy as second-line therapy for advanced ALK+ non-small cell lung cancer (NSCLC).

In this phase III trial, Crinò says, crizotinib showed superior activity compared with chemotherapy in patients with ALK+ NSCLC. Crizotinib showed a response rate of 65-70% compared to standard therapy, which only showed a response rate of about 10-28%, Crinò says.

There was also a significant improvement in progression-free survival. While standard treatments such as chemotherapy only show a progression-free survival rate of 3.5 months, Crinò says, there is a progression-free survival rate approaching 8 or 9 months with crizotinib.

View more from the 2013 European Cancer Congress

Videos

Lucio CrinÃ², MD, discusses the results of the PROFILE 1007 trial that compared crizotinib with standard chemotherapy as second-line therapy for advanced ALK+ non-small cell lung cancer

Lucio CrinÃ², MD

Articles

Dr. CrinÃ² on Crizotinib in ALK-Positive NSCLC